VIPR1 and colitis: Furthermore, male VIP KO mice or wild-type mice treated with a pan-VIP receptor antagonist (VIP-hybrid101) or the selective VPAC1 antagonist (PG97-269)15 are resistant to DSS-induced colitis with reduced levels of colonic inflammatory mediators and cytokines102, suggesting that VIP acts as a pro-inflammatory mediator.